Models to predict intestinal absorption of therapeutic peptides and proteins

Current Drug Metabolism

Volumn 14, Issue 1, 2013, Pages 4-20

  Antunes, Filipa ^a   Andrade, Fernanda ^a   Ferreira, Domingos ^a   Nielsen, Hanne Mørck ^b   Sarmento, Bruno ^a,c  

^a UNIVERSITY OF PORTO   (Portugal)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c UNIVERSITY INSTITUTE OF HEALTH SCIENCES IUCS   (Portugal)

Author keywords

Drug screening; In vitro in vivo correlation; Intestinal absorption; Permeability prediction; Therapeutic proteins

Indexed keywords

POLYAMIDOAMINE;

ANIMAL CARE; ANIMAL CELL; ARTICLE; B LYMPHOCYTE; CELL LINE; COCULTURE; COMPUTER MODEL; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DEVELOPMENT; DRUG INDUSTRY; EX VIVO STUDY; HUMAN; HUMAN CELL; IN VIVO STUDY; INTESTINE ABSORPTION; INTESTINE MUCOSA PERMEABILITY; NONHUMAN;

EID: 84871348189     PISSN: 13892002     EISSN: 18755453     Source Type: Journal    
DOI: 10.2174/138920013804545160     Document Type: Article

References (141)

1. Brodin, B.; Nielsen, C. U.; Teffansen, B.; Frøkjær, S. Transport of Peptidomimetic Drugs by the Intestinal Di/tri-peptide Transporter, PepT1. Pharmacol. Toxicol., 2002, 90(6), 285-296.
2. Pelkonen, O.; Boobis, A. R.; Gundert-Remy, U. In vitro prediction of gastrointestinal absorption and bioavailability: an experts' meeting report. Eur. J. Clin. Pharmacol., 2001, 57(9), 621-629.
3. Frokjaer, S.; Otzen, D. D. Protein drug stability: a formulation challenge. Nat. Rev. Drug Discovery, 2005, 4, 298-306.
4. Emami, J. In vitro - In vivo correlation: From theory to applications. J. Pharm. Sci., 2006, 9(2), 31-51.
5. Shah, R. B.; Ahsan, F.; Khan, M. A. Oral delivery of proteins: progress and prognostication. Crit Rev Ther Drug Carrier Syst., 2002, 19(2), 135-169.
6. Lennernäs, H. Animal data: The contributions of the Ussing Chamber and perfusion systems to predicting human oral drug delivery in vivo. Adv. Drug Deliv. Rev., 2007, 59(11), 1103-1120.
7. Salamat-Miller, N.; Johnston, T. P. Current strategies used to enhance the paracellular transport of therapeutic polypeptides across the intestinal epithelium. Int. J. Pharm., 2005, 294(1-2), 201-216.
8. Rubio-Aliaga, I.; Daniel, H. Mammalian peptide transporters as targets for drug delivery. Trends Pharmacol. Sci., 2002, 23(9), 434-440.
9. Fearn, R. A.; Hirst, B. H. Predicting oral drug absorption and hepatobiliary clearance: Human intestinal and hepatic in vitro cell models. Environ. Toxicol. Pharmacol., 2006, 21(2), 168-178.
10. Pauletti, G. M.; Gangwar, S.; Knipp, G. T.; Nerurkar, M. M.; Okumu, F. W.; Tamura, K.; Siahaan, T. J.; Borchardt, R. T. Structural requirements for intestinal absorption of peptide drugs. J. Controlled Release, 1996, 41(1-2), 3-17.
11. Bendayan, M.; Ziv, E.; Gingras, D.; Ben-Sasson, R.; Bar-On, H.; Kidron, M. Biochemical and morpho-cytochemical evidence for the intestinal absorption of insulin in control and diabetic rats. Comparison between the effectiveness of duodenal and colon mucosa. Diabetologia, 1994, 37(2), 119-126.
12. Ziv, E.; Bendayan, M. Intestinal absorption of peptides through the enterocytes. Microsc. Res Tech., 2000, 49(4), 346-352.
13. Morishita, M.; Morishita, I.; Takayama, K.; Machida, Y., Nagai, T. Site-dependent effect of aprotinin, sodium caprate, Na2EDTA and sodium glycocholate on intestinal absorption of insulin. Biol. Pharm. Bull., 1993, 16(1), 68-72.
14. Ferrec, E. L.; Chesne, C.; Artusson, P.; Brayden, D.; Fabre, G.; Gires, P.; Guillou, F.; Rousset, M. In vitro models of the intestinal barrier. The report and recommendations of ECVAM Workshop 46. European Centre for the Validation of Alternative methods. Alternatives to animal testing, 2001, 29(6), 649-668.
15. Makhlof, A.; Werle, M.; Tozuka, Y.; Takeuchi, H.: A mucoadhesive nanoparticulate system for the simultaneous delivery of macromolecules and permeation enhancers to the intestinal mucosa. J. Controlled Release, 2010.
16. Aungst, B. J. Intestinal permeation enhancers. J. Pharm. Sci., 2000, 89(4), 429-442.
17. Jang, M. H.; Kweon, M. N.; Iwatani, K.; Yamamoto, M.; Terahara, K.; Sasakawa, C.; Suzuki, T.; Nochi, T. Intestinal villous M cells: an antigen entry site in the mucosal epithelium. PNAS. 2004, 101, 6110-6115.
18. Borges, O.; Cordeiro-da-Silva, A.; Romeijn, S. G.; Amidi, M.; de Sousa, A.; Borchard, G.; Junginger, H. E. Uptake studies in rat Peyer's patches, cytotoxicity and release studies of alginate coated chitosan nanoparticles for mucosal vaccination. J. Controlled Release. 2006, 114(3), 348-358.
19. Fasano, A. Innovative strategies for the oral delivery of drugs and peptides. Trends Biotechnol., 1998, 16, 152-157.
20. des Rieux, A.; Fievez, V.; Garinot, M.; Schneider, Y.-J.; Preat, V. Nanoparticles as potential oral delivery systems of proteins and vaccines: A mechanistic approach. J. Controlled Release, 2006, 1161-27.
21. Hussain, N.; Jaitley, V.; Florence, A. T. Recent advances in the understanding of uptake of microparticulates across the gastrointestinal lymphatics. Adv. Drug Deliv. Rev., 2001, 50, 107-142.
22. des Rieux, A.; Fievez, V.; Theate, I.; Mast, J.; Preat, V., Schneider, Y.-J. An improved in vitro model of human intestinal follicle-associated epithelium to study nanoparticle transport by Ms cells. Eur. J. Pharm. Sci., 2007, 30(5), 380-391.
23. Park, J. W.; Kim, S. K.; Al-Hilal, T. A.; Jeon, O. C.; Moon, H. T.; Byun, Y. Strategies for Oral Delivery of Macromolecule Drugs. Biotechnol. Bioprocess. Eng., 2010, 15, 66-75.
24. Kowapradit, J.; Opanasopit, P.; Ngawhirunpat, T.; Apirakaramwong, A.; Rojanarata, T.; Ruktanonchai, U.; Sajomsang, W. In vitro permeability enhancement in intestinal epithelial cells (Caco-2) monolayer of water soluble quaternary ammonium chitosan derivatives. AAPS. Pharm. Sci. Tech., 2010, 11(2), 497-508.
25. Lin, Y.; Fujimori, T.; Kawaguchi, N.; Tsujimoto, Y.; Nishimi, M.; Dong, Z.; Katsumi, H.; Sakane, T. Polyamidoamine dendrimers as novel potential absorption enhancers for improving the small intestinal absorption of poorly absorbable drugs in rats. J. Controlled Release, 2010, 149(1), 21-28.
26. Maher, S.; Devocelle, M.; Ryan, S.; McClean, S.; Brayden, D. J. Impact of amino acid replacements on in vitro permeation enhancement and cytotoxicity of the intestinal absorption promoter, melittin. Int. J. Pharm., 2010, 387, 154-160.
27. Pabla, D.; Akhlaghi, F.; Zia, H. Intestinal permeability enhancement of levothyroxine sodium by straight chain fatty acids studied in MDCK epithelial cell line. Eur. J. Pharm. Sci., 2010, 40(5), 466-472.
28. Dokoumetzidis, A.; Kalantzi, L.; Fotaki, N. Predictive models for oral drug absorption: from in silico methods to integrated dynamical models Expert Opin. Drug Metab., Toxicol. 2007 3(4), 491-505.
29. Amidon, G. L.; Lennernas, H.; Shah, V. P.; Crison, J. R. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm. Res., 1995, 12, 413-420.
30. Hou, T.; Wang, J.; Zhang, W.; Wang, W.; Xu, X. Recent advances in computational prediction of drug absorption and permeability in drug discovery. Curr. Med. Chem., 2006, 13(22), 2653-2667.
31. Hämäläinen, M. D.; Frostell-Karlsson, A. Predicting the intestinal absorption potential of hits and leads. Drug Discov Today: Technol., 2004, 1(4), 397-405.
32. Egan, W. J.; Lauri, G. Prediction of intestinal permeability. Adv. Drug Deliv. Rev., 2002, 54, 273-289.
33. Ungell, A. L.; Karlsson, J. Cell Cultures in Drug Discovery: An Industrial Perspective Wiley-VCH Verlag GmbH & Co. KGaA 2004.
34. Huang, W.; Lee, S., Yu, L. Mechanistic Approaches to Predicting Oral Drug Absorption. AAPS J., 2009, 11(2), 217-224.
35. Waterbeemd, H. V.; Gifford, E. ADMET in silico modelling: towards prediction paradise? Nat. Rev. Drug Discovery, 2003, 2(3), 192-204.
36. Ecker, G. F.; Noe, C. R. In silico prediction models for blood-barrier permeation. Curr. Med. Chem., 2004, 11(12), 1617-1628.
37. Jung, E.; Kim, J.; Kim, M.; Jung, D.; Rhee, H.; Shin, J.-M.; Choi, K.; Kang, S.-K.; Kim, M.-K.; Yun, C.-H.; Choi, Y.-J.; Choi, S.-H. Artificial neural network models for prediction of intestinal permeability of oligopeptides. BMC Bioinf., 2007, 8(1), 245.
38. Polli, J. In vitro studies are sometimes better than conventional human pharmacokinetic in vivo studies in assessing bioequivalence of immediate-release solid oral dosage forms AAPS J., 2008, 10(2), 289-299.
39. Balimane, P. V.; Chong, S.; Morrison, R. A. Current methodologies used for evaluation of intestinal permeability and absorption. J. Pharmacol. Toxicol., 2000, 44 (301-312).
40. Cheng, K. C.; Li, C.; Uss, A. S. Prediction of oral drug absorption in humans - from cultured cell lines and experimental animals. Expert Opin. Drug Metab. Toxicol., 2008, 4(5), 581-590.
41. Gaspar, R.; Duncan, R. Polymeric carriers: preclinical safety and the regulatory implications for design and development of polymer therapeutics. Adv. Drug Deliv. Rev., 2009, 61(13), 1220-1231.
42. Fotaki, N. Pros and cons of methods used for the prediction of oral drug absorption. Expert Rev. Clin. Pharmacol., 2009, 2, 195-208.
43. Bohets, H.; Annaert, P.; Mannens, G.; Beijsterveldt, L.v.; Anciaux, K.; Verboven, P.; Meuldermans, W.; Lavrijsen, K. Strategies for Absorption Screening in Drug Discovery and Development. Curr. Top. Med. Chem., 2001, 1, 367-383.
44. Volpe, D. A. Variability in Caco-2 and MDCK cell-based intestinal permeability assays. J. Pharm. Sci., 2008, 97, 712-725.
45. Fogh, J.; Orfeo, T.; Tiso, J.; Sharkey, F. E. Establishment of human colon carcinoma lines in nude mice. Exp. Cell Biol., 1979, 47(2), 136-144.
46. Hilgendorf, C.; Spahn-Langguth, H.; Regardh, C. G.; Lipka, E.; Amidon, G. L.; Langguth, P. Caco-2 versus Caco-2/HT29-MTX cocultured cell lines: permeabilities via diffusion, inside-and outsidedirected carrier-mediated transport. J. Pharm. Sci., 2000, 89(1), 63-75.
47. Rubas, W.; Cromwell, M. E.; Shahrokh, Z.; Villagran, J.; Nguyen, T. N.; Wellton, M.; Nguyen, T. H.; Mrsny, R. J. Flux measurements across Caco-2 monolayers may predict transport in human large intestinal tissue. J. Pharm. Sci., 1996, 85(2), 165-169.
48. Matsson, P.; Bergstrom, C. A. S.; Nagahara, N.; Tavelin, S.; Norinder, U.; Artursson, P. Exploring the Role of Different Drug Transport Routes in Permeability Screening. J. Med. Chem., 2005, 48(2), 604-613.
49. Artursson, P. Cell cultures as models for drug absorption across the intestinal mucosa. Crit. Rev. Ther. Drug Carrier Syst., 1991, 8, 305-330.
50. Walter, E.; Kissel, T. Heterogeneity in the human intestinal cell line Caco-2 leads to differences in transepithelial transport. Eur. J. Pharm. Sci., 1995, 3, 215-230.
51. Artursson, P.; Palm, K.; Luthman, K. Caco-2 monolayers in experimental and theoretical predictions of drug transport. Adv. Drug Deliv. Rev., 2001, 46, 27-43.
52. Kim, S.; Lee, H.; Lee, S.; Kim, S. K.; Lee, Y. K.; Chung, B. H.; Moon, H. T.; Byun, Y. Enhancing effect of chemically conjugated deoxycholic acid on permeability of calcitonin in Caco-2 cells. Drug Dev. Res., 2005, 64(2), 129-135.
53. Sajeesh, S.; Vauthier, C.; Gueutin, C.; Ponchel, G.; Sharma, C. P. Thiol functionalized polymethacrylic acid-based hydrogel microparticles for oral insulin delivery. Acta Biomater., 2010, 6(8), 3072-3080.
54. Katsikari, A.; Patronidou, C.; Kiparissides, C., Arsenakisa, M. Uptake and cytotoxicity of poly (d, l-lactide-co-glycolide) nanoparticles in human colon adenocarcinoma cells. Mater. Sci. Eng. B., 2009, 165, 160-164.
55. Sweet, D. M.; Kolhatkar, R. B.; Ray, A.; Swaan, P.; Ghandehari, H. Transepithelial transport of PEGylated anionic poly (amidoamine) dendrimers: Implications for oral drug delivery. J. Controlled Release, 2009, 138, 78-85.
56. Skolnik, S.; Lin, X.; Wang, J.; Chen, X.-H.; He, T.; Zhang, B. Towards prediction of in vivo intestinal absorption using a 96-well Caco-2 assay. J. Pharm. Sci., 2010, 99(7), 3246-3265.
57. Cho, M. J.; Thompson, D. P.; Cramer, C. T.; Vidmar, T. J.; Scieszka, J. F. The Madin Darby Canine Kidney (MDCK) epithelial cell monolayer as a model cellular transport barrier. Pharm. Res., 1989, 6, 71-77.
58. Avdeef, A.; Tam, K. Y. How Well Can the Caco-2/Madin-Darby Canine Kidney Models Predict Effective Human Jejunal Permeability? J. Med. Chem., 2010, 53(9), 3566-3584.
59. Balimane, P. V.; Chong, S. Cell culture-based models for intestinal permeability: a critique. Drug Discov. Today, 2005, 10(5), 335-343.
60. Irvine, J. D.; Takahashi, L.; Lockhart, K.; Cheong, J.; Tolan, J. W.; Selick, H. E.; Grove, J. R. MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening J. Pharm. Sci., 2000, 88(1), 28-33.
61. Monlauzeur, L.; Breuza, L.; Bivic, A. L. Different Functional Recognition of Basolateral Signals in Caco-2 and MDCK Cells Exp. Cell Res., 2000, 258(1), 195-203.
62. Putnam, W. S.; Pan, L.; Tsutsui, K.; Takahashi, L.; Benet, L. Z. Comparison of Bidirectional Cephalexin Transport across MDCK and Caco-2 Cell Monolayers: Interactions with Peptide Transporters. Pharm. Res., 2002, 19(1), 27-33.
63. Deferme, S.; Annaert, P.; Augustijns, P. In Vitro Screening Models to Assess Intestinal Drug Absorption and Metabolism. In: Kim, C. E.a. K.-J., Ed. Drug Absorption Studies. vol. Volume VII, Springer US 2008.
64. Luo, S.; Kansara, V. S.; Zhu, X.; Pal, D.; Mitra, A. K. Functional Characterization of Sodium-dependent Multivitamin Transporter (SMVT) in MDCK-MDR1 cells and its Utilization as a Target for Drug Delivery. Mol. Pharmacol., 2006, 3(3), 329-339.
65. Tréhin, R.; Krauss, U.; Beck-Sickinger, A.; Merkle, H.; Nielsen, H. Cellular Uptake But Low Permeation of Human Calcitonin-Derived Cell Penetrating Peptides and Tat (47-57) Through Well-Differentiated Epithelial Models. Pharm. Res., 2004, 21(7), 1248-1256.
66. Maher, S.; Feighery, L.; Brayden, D.; McClean, S. Melittin as a Permeability Enhancer II: In Vitro Investigations in Human Mucus Secreting Intestinal Monolayers and Rat Colonic Mucosae. Pharm. Res., 2007, 24(7), 1346-1356.
67. Lesuffleur, T.; Barbat, A.; Dussaulx, E.; Zweibaum, A. Growth adaptation to methotrexate of HT-29 human colon carcinoma cells is associated with their ability to differentiate into columnar absorptive and mucus-secreting cells. Cancer Res., 1990, 50(19), 6334-6343.
68. Walter, E.; Janich, S.; Roessler, B. J.; Hilfinger, J. M.; Amidon, G. L. HT29-MTX/Caco-2 cocultures as an in vitro model for the intestinal epithelium: In vitro-in vivo correlation with permeability data from rats and humans. J. Pharm. Sci., 1996, 85(10), 1070-1076.
69. Wikman-Larhed, A.; Artursson, P. Co-cultures of human intestinal goblet (HT29-H) and absorptive (Caco-2) cells for studies of drug and peptide absorption. Eur. J. Pharm. Sci., 1995, 3(3), 171-183.
70. Nollevaux, G.; Deville, C.; El Moualij, B.; Zorzi, W.; Deloyer, P.; Schneider, Y. J.; Peulen, O.; Dandrifosse, G. Development of a serum-free co-culture of human intestinal epithelium cell-lines (Caco-2/HT29-5M21). BMC. Cell Biol., 2006, 7, 20.
71. Keely, S.; Rullay, A.; Wilson, C.; Carmichael, A.; Carrington, S.; Corfield, A.; Haddleton, D. M.; Brayden, D. J. In Vitro and ex Vivo Intestinal Tissue Models to Measure Mucoadhesion of Poly (Methacrylate) and N-Trimethylated Chitosan Polymers. Pharm. Res., 2005, 22(1), 38-49.
72. Schipper, N. G. M.; Varum, K. M.; Stenberg, P.; Ocklind, G.; Lennernas, H.; Artursson, P. Chitosans as absorption enhancers of poorly absorbable drugs 3: Influence of mucus on absorption enhancement. Eur. J. Pharm. Sci., 1999, 8, 335-343.
73. Pontier, C.; Pachot, J.; Botham, R.; Lenfant, B.; Arnaud, P. HT29-MTX and Caco-2/TC7 monolayers as predictive models for human intestinal absorption: role of the mucus layer. J. Pharm. Sci., 2001, 90(10), 1608-1619.
74. Carr, D. A.; Peppas, N. A. Assessment of poly (methacrylic acid-co-N-vinyl pyrrolidone) as a carrier for the oral delivery of therapeutic proteins using Caco-2 and HT29-MTX cell lines. J. Biomed. Mater. Res-A., 2010, 92 A (2), 504-512.
75. Wood, K. M.; Stone, G. M.; Peppas, N. A. The effect of complexation hydrogels on insulin transport in intestinal epithelial cell models. Acta Biomaterialia, 2010, 6(1), 48-56.
76. Fonte, P.; Nogueira, T.; Gehm, C.; Ferreira, D.; Sarmento, B. Chitosan-coated solid lipid nanoparticles enhance the oral absorption of insulin. Drug Deliv. and Transl. Res., 2011, 1-10.
77. Antunes, F.; Andrade, F.; Ferreira, D.; Sarmento, B.; Comparison of two triple co-culture in vitro cell models to predict intestinal absorption of peptidic drugs, Pharmaceutical Sciences World Congress (PSWC), Morial Convention Center New Orleans, Louisiana, USA, 2010
78. Gullberg, E.; Leonard, M.; Karlsson, J.; Hopkins, A. M.; Brayden, D.; Baird, A. W.; Artursson, P. Expression of Specific Markers and Particle Transport in a New Human Intestinal M-Cell Model. Biochem. Biophys. Res. Commun., 2000, 279(3), 808-813.
79. Kerneis, S.; Bogdanova, A.; Kraehenbuhl, J.-P.; Pringault, E. Conversion by Peyer's Patch Lymphocytes of Human Enterocytes into M Cells that Transport Bacteria. Science. 1997, 277(5328), 949-952.
80. Lubben, I. M. V. D.; Opdorp, F. A. C. V.; Hengeveld, M. R.; Onderwater, J. J. M.; Koerten, H. K.; Verhoef, J. C.; Borchard, G.; Junginger, H. E. Transport of Chitosan Microparticles for Mucosal Vaccine Delivery in a Human Intestinal M-cell Model. J. Drug Targeting, 2002, 10(6), 449-456.
81. Lai, Y. H.; D'Souza, M. J. Microparticle transport in the human intestinal M cell model. J. Drug Targeting, 2008, 16, 36-42.
82. Kadiyala, I.; Loo, Y.; Roy, K.; Rice, J.; Leong, K. W. Transport of chitosan-DNA nanoparticles in human intestinal M-cell model versus normal intestinal enterocytes. Eur. J. Pharm. Sci., 2010, 39, 103-109.
83. Rieux, A.d.; Fievez, V.; Momtaz, M.; Detrembleur, C.; Alonso-Sande, M.; Gelder, J. V.; Cauvin, A.; Schneider, Y.-J. Heloderminloaded nanoparticles: Characterization and transport across an in vitro model of the follicle-associated epithelium. J. Controlled Release, 2007, 118, 294-302.
84. Akande, J.; Yeboah, K. G.; Addo, R. T.; Siddig, A.; Oettinger, C. W.; D'Souza, M. J. Targeted delivery of antigens to the gut-associated lymphoid tissues: 2. Ex vivo evaluation of lectin-labelled albumin microspheres for targeted delivery of antigens to the M-cells of the Peyer's patches. J. Microencapsulation, 2010, 27(4), 325-336.
85. Mudra, D. R.; Jin, J. Y.; Borchardt, R. T. Absorption Barriers in the Rat Intestinal Mucosa: 2. Application of Physiologically Based Mathematical Models to Quantify Mechanisms of Drug Permeation and Metabolism. J. Pharm. Sci., 2010, 99(2), 999-1015.
86. Fagerholm, U.; Johansson, M.; Lennernäs, H. Comparison Between Permeability Coefficients in Rat and Human Jejunum. Pharm. Res., 1996, 13(9), 1336-1342.
87. Cao, X.; Gibbs, S. T.; Fang, L.; Miller, H. A.; Landowski, C. P.; Shin, H.-C.; Lennernas, H.; Zhong, Y. Why is it challenging to predict intestinal drug absorption and oral bioavailability in human using rat model. Pharm. Res., 2006, 23(8), 1675-1686.
88. Masaki, K.; Hashimoto, M.; Imai, T. Intestinal First-Pass Metabolism via Carboxylesterase in Rat Jejunum and Ileum. Drug Metab. Dispos., 2007, 35, 1089-1095.
89. Mudra, D. R.; Borchardt, R. T. Absorption Barriers in the Rat Intestinal Mucosa: 1. Application of an In Situ Perfusion Model to Simultaneously Assess Drug Permeation and Metabolism. J. Pharm. Sci., 2010, 99(2), 982-998.
90. Takahashi, M.; Washio, T.; Suzuki, N.; Igeta, K.; Yamashita, S. Investigation of the Intestinal Permeability and First-Pass Metabolism of Drugs in Cynomolgus Monkeys Using Single-Pass Intestinal Perfusion. Biol. Pharm. Bull., 2010, 33(1), 111-116.
91. Lin, Y.; Fujimori, T.; Kawaguchi, N.; Tsujimoto, Y.; Nishimi, M.; Dong, Z.; Katsumi, H.; Sakane, T. Polyamidoamine dendrimers as novel potential absorption enhancers for improving the small intestinal absorption of poorly absorbable drugs in rats. J. Controlled Release., 2010.
92. Kamei, N.; Morishita, M.; Takayama, K. Importance of intermolecular interaction on the improvement of intestinal therapeutic peptide/protein absorption using cell-penetrating peptides. J. Controlled Release, 2009, 136(3), 179-186.
93. Yin, L.; Ding, J.; Zhang, J.; He, C.; Tang, C.; Yin, C. Polymer integrity related absorption mechanism of superporous hydrogel containing interpenetrating polymer networks for oral delivery of insulin. Biomaterials, 2010, 31(12), 3347-3356.
94. Ussing, H. H.; Zerahn, K. Active transport of sodium as the source of electric current in the short-circuited isolated frog skin. Acta Physiol. Scand., 1951, 23, 110-127.
95. Grass, G. M.; Sweetana, S. A. In vitro Measurement of gastrointestinal tissue permeability using a new diffusion cell. Pharm. Res., 1988, 5, 372-376.
96. Plumb, J. A.; Burston, D.; Baker, T. G.; Gardner, M. L. G. A comparison of the structural integrity of several commonly used preparations of rat small intestine in vitro. Clin. Sci., 1987, 73, 53-59.
97. Söderholm, J. D.; Hedman, L.; Artursson, P.; Franzén, L.; Larsson, J.; Pantzar, N.; Permert, J.; Olaison, G. Integrity and metabolism of human ileal mucosa in vitro in the Ussing chamber. Acta Physiol. Scand., 1998, 162, 47-56.
98. Ungell, A. L.; Nylander, S.; Bergstrand, S.; Sjöberg, Å.; Lennernäs, H. Membrane transport of drugs in different regions of the intestinal tract of the rat. J. Pharm. Sci., 1998, 87(3), 360-366.
99. Okudaira, N.; Tatebayashi, T.; Speirs, G. C.; Komiya, I.; Sugiyama, Y. A study of the intestinal absorption of an ester-type prodrug, ME3229, in rats: active efflux transport as a cause of poor bioavailability of the active drug. J. Pharmacol. Exp. Ther., 2000, 294(2), 580-587.
100. Boisset, M.; Botham, R. P.; Haegele, K. D.; Lenfant, B.; Pachot, P. I. Absorption of angiotensin II antagonists in Ussing chambers, Caco-2, perfused jejunum loop and in vivo: Importance of drug ionisation in the in vitro prediction of in vivo absorption. Eur. J. Pharm. Sci., 2000, 10, 215-224.
101. Naruhashi, K.; Tamai, I.; Sai, Y.; Suzuki, N.; J. Tsuji, A. Secretory transport of p-aminohippuric acid across intestinal epithelial cells in Caco-2 cells and isolated intestinal tissue. J. Pharm. Pharmacol., 2001, 53, 73-81.
102. Saitoh, S., Aungst, B. J.: Possible involvement of multiple Pglycoprotein-mediated efflux systems in the transport of verpamil and other organic cations across rat intestine. Pharm. Res., 1995, 12, 1304-1310.
103. Annaert, P.; Brouwers, J.; Bijnens, A.; Lammert, F.; Tack, J.; Augustijns, P. Ex vivo permeability experiments in excised rat intestinal tissue and in vitro solubility measurements in aspirated human intestinal fluids support age-dependent oral drug absorption. Eur. J. Pharm. Sci., 2010, 39, 15-22.
104. Föger, F.; Kopf, A.; Loretz, B.; Albrecht, K.; Bernkop- Schnürch, A. Correlation of in vitro and in vivo models for the oral absorption of peptide drugs. Amino Acids, 2008, 35(1), 233-241.
105. Shah, R. B.; Khan, M. A. Regional Permeability of Salmon Calcitonin in Isolated Rat Gastrointestinal Tracts: Transport Mechanism Using Caco-2 Cell Monolayer. AAPS J., 2004, 6 (4).
106. Delie, F. Evaluation of nano-and microparticle uptake by the gastrointestinal tract. Adv. Drug Deliv. Rev., 1998, 34, 221-233.
107. Chung, H.; Kim, J.; Um, J.; Kwon, I.; Jeong, S. Self-assembled "nanocubicle" as a carrier for peroral insulin delivery. Diabetologia, 2002, 45, 448-451.
108. Garcia-Fuentes, M.; Prego, C.; Torres, D.; Alonso, M. J. A comparative study of the potential of solid triglyceride nanostructures coated with chitosan or poly (ethylene glycol) as carriers for oral calcitonin delivery. Eur. J. Pharm. Sci., 2005, 25, 123-133.
109. Sutton, S. C. Companion animal physiology and dosage form performance. Adv. Drug Deliv. Rev., 2004, 56(10), 1383-1398.
110. Chiou, W. L.; Buehler, P. W. Comparison of Oral Absorption and Bioavailability of Drugs between Monkey and Human. Pharm. Res., 2002, 19 (6).
111. Dressman, J. B.; Reppas, C. In vitro-in vivo correlations for lipophilic, poorly water-soluble drugs. Eur. J. Pharm. Sci., 2000, 11(2), S73-S80.
112. Fotaki, N.; Symillides, M.; Reppas, C.; Canine versus in vitro data for predicting input profiles of l-sulpiride after oral administration. Eur. J. Pharm. Sci., 2005, 26, 324-333.
113. Sunesen, V. H.; Pedersen, B. L.; Kristensen, H. G.; Müllertz, A. In vivo in vitro correlations for a poorly soluble drug, danazol, using the flow-through dissolution method with biorelevant dissolution media. Eur. J. Pharm. Sci., 2005, 24, 305-313.
114. Zhao, Y. H.; Abraham, M. H.; Le, J.; Hersey, A.; Luscombe, C. N.; Beck, G.; Sherborne, B.; Cooper, I. Evaluation of rat intestinal absorption data and correlation with human intestinal absorption. Eur. J. Med. Chem., 2003, 38 233-243.
115. Lu, A. Y. H.; Lin, J. H. Applications and limitations of interspecies scaling and in vitro extrapolation in pharmacokinetics. Drug Metab. Dispos., 1998, 26(12), 1202-1212.
116. Gardner, N.; Haresign, W.; Spiller, R.; Farraj, N.; Wiseman, J.; Norbury, H.; Illum, L. Development and validation of a pig model for colon-specific drug delivery. J. Pharm. Pharmacol., 1996, 48(7), 689-693.
117. Tugrul, T. K. Comparison of the gastrointestinal anatomy, physiology, and biochemistry of humans and commonly used laboratory animals. Biopharm. Drug Dispos., 1995, 16(5), 351-380.
118. Frick, L. W.; Adkison, K. K.; Wells-Knecht, K. J.; Woollard, P.; Higton, D. M. Cassette dosing: rapid in vivo assessment of pharmacokinetics. Pharm. Sci. Tech. Today, 1998, 1, 12-18.
119. Lipinski, C. A. Drug-like properties and the causes of poor solubility and poor permeability. J. Pharmacol. Toxicol., 2000, 44, 235-249.
120. Takatsuka, S.; Morita, T.; Koguchi, A.; Horikiri, Y.; Yamahara, H.; Yoshino, H. Synergistic absorption enhancement of salmon calcitonin and reversible mucosal injury by applying a mucolytic agent and a non-ionic surfactant. Int. J. Pharm., 2006, 316(1-2), 124-130.
121. Woitiski, C. B.; Neufeld, R. J.; Veiga, F.; Carvalho, R. A.; Figueiredo, I. V. Pharmacological effect of orally delivered insulin facilitated by multilayered stable nanoparticles. Eur. J. Pharm. Sci., 2010, 41(3-4), 556-563.
122. Sarmento, B.; Ribeiro, A.; Veiga, F.; Sampaio, P.; Neufeld, R.; Ferreira, D. Alginate/chitosan nanoparticles are effective for oral Insulin delivery. Pharm. Res., 2007, 24(12), 2198-2206.
123. Sarmento, B.; Ribeiro, A.; Veiga, F.; Ferreira, D.; Neufeld, R. Oral bioavailability of insulin contained in polysaccharide nanoparticles. Biomacromolecules. 2007, 8(10), 3054-3060.
124. Sarmento, B.; Martins, S.; Ferreira, D.; Souto, E. Oral insulin delivery by means of solid lipid nanoparticles. Int. J. Nanomed., 2007, 2(4), 743-749.
125. Martins, S.; Silva, A.; Ferreira, D.; Souto, E. Improving Oral Absorption of Samon Calcitonin by Trimyristin Lipid Nanoparticles. J. Biomed. Nanotechnol., 2009, 5, 76-83.
126. Bayat, A.; Dorkoosh, F. A.; Dehpour, A. R.; Moezi, L.; Larijani, B.; Junginger, H. E.; Rafiee-Tehrani, M. Nanoparticles of quaternized chitosan derivatives as a carrier for colon delivery of insulin: ex vivo and in vivo studies. Int. J. Pharm., 2008, 356(1-2), 259-266.
127. Tang, C.; Yu, J.; Yin, L.; Yin, C.; Pei, Y. Transport of Insulin in Modified Valia-Chien Chambers and Caco-2 Cell Monolayers. Drug Dev. Ind. Pharm., 2007, 33(4), 449-456.
128. Sandri, G.; Bonferoni, M.; Rossi, S.; Ferrari, F.; Boselli, C.; Caramella, C. Insulin-Loaded Nanoparticles Based on N-Trimethyl Chitosan: In Vitro (Caco-2 Model) and Ex Vivo (Excised Rat Jejunum, Duodenum, and Ileum) Evaluation of Penetration Enhancement Properties. AAPS Pharm. Sci. Tech., 2010, 11(1), 362-371.
129. Perakslis, E.; Tuesca, A.; Lowman, A. Complexation hydrogels for oral protein delivery: an in vitro assessment of the insulin transportenhancing effects following dissolution in simulated digestive fluids. J. Biomat. Sci-Polym. E., 2007, 18(12), 1475-1490.
130. Sadeghi, A. M. M.; Dorkoosh, F. A.; Avadi, M. R.; Weinhold, M.; Bayat, A.; Delie, F.; Gurny, R.; Larijani, B. Permeation enhancer effect of chitosan and chitosan derivatives: Comparison of formulations as soluble polymers and nanoparticulate systems on insulin absorption in Caco-2 cells. Eur. J. Pharm. Biopharm., 2008, 70(1), 270-278.
131. Torres-Lugo, M.; García, M.; Record, R.; Peppas, N. A. pH-Sensitive Hydrogels as Gastrointestinal Tract Absorption Enhancers: Transport Mechanisms of Salmon Calcitonin and Other Model Molecules Using the Caco-2 Cell Model. Biotechnol. Progr., 2002, 18(3), 612-616.
132. Wu, S.-J.; Robinson, J. R. Transport of human growth hormone across Caco-2 cells with novel delivery agents: evidence for P-glycoprotein involvement. J. Controlled Release. 1999, 62(1-2), 171-177.
133. Maculotti, K.; Tira, E.; Sonaggere, M.; Perugini, P.; Conti, B.; Modena, T.; Pavanetto, F. In vitro evaluation of chondroitin sulphate-chitosan microspheres as carrier for the delivery of proteins J. Microencapsulation, 2009, 26(6), 535-543.
134. Chen, F.; Zhang, Z.-R.; Yuan, F.; Qin, X.; Wang, M.; Huang, Y. In vitro and in vivo study of N-trimethyl chitosan nanoparticles for oral protein delivery. Int. J. Pharm., 2008, 349, 226-233.
135. Shu, S.; Zhang, X.; Wu, Z.; Wang, Z.; Li, C. Gradient cross-linked biodegradable polyelectrolyte nanocapsules for intracellular protein drug delivery. Biomaterials, 2010, 31(23), 6039-6049.
136. Zhang, Y.; Yang, X.; Wang, K. Permeation of vanadium (III, IV, V)-dipicolinate complexes across MDCK cell monolayer and comparison with Caco-2 cells. Chin. Sci. Bull., 2005, 50(17), 1854-1859.
137. Shofner, J. P.; Phillips, M. A.; Peppas, N. A. Cellular Evaluation of Synthesized Insulin/Transferrin Bioconjugates for Oral Insulin Delivery Using Intelligent Complexation Hydrogels. Macromol. Biosci., 2010, 10(3), 299-306.
138. Shah, R. B.; Khan, M. A. Regional permeability of salmon calcitonin in isolated rat gastrointestinal tracts: transport mechanism using Caco-2 cell monolayer. AAPS J., 2004, 6 (4).
139. Jung, E.; Kim, J.; Kim, M.; Jung, D. H.; Rhee, H.; Shin, J.-M.; Choi, K.; Kang, S.-K. Artificial neural network models for prediction of intestinal permeability of oligopeptides. BMC Bioinf., 2007, 8 (245).
140. Lin, J. H. Applications and Limitations of Interspecies Scaling and In Vitro Extrapolation in Pharmacokinetics. Drug Metab. Dispos., 1998, 26(12), 1202-1212.
141. Goldberg, M.; Gomez-Orellana, I. Challenges for the oral delivery of macromolecules. Nat. Rev. Drug Discov., 2003, 2(4), 289-295.